EXETER, NH – 2018 – Vapotherm, Inc. today announced the publication of a key prospective, multi-center, controlled, order-randomized crossover trial. The study demonstrates that using the IntellO2 automated oxygen controller module helped clinicians maintain neonates in the physician-prescribed oxygen saturation range significantly better than manual control alone.
The results were published by Reynolds and colleagues in the Archives of Disease in Childhood: Fetal and Neonatal Edition, entitled “Randomised crossover study of automated oxygen control for preterm infants receiving nasal High Flow.” The data show that trained staff were able to keep the babies’ oxygen saturation in the target range 49% of the time with manual controls alone. When using the IntellO2 module staff was able to maintain the babies in range 80% of the time.
“We are very pleased with these results. This study shows the ability of the IntellO2 to help clinicians maintain premature babies in the prescribed target pulse oxygenation range. We now have strong evidence that when compared to manual control, using the IntellO2 improves the ability to keep babies within target saturation range,” said Joe Army, CEO of Vapotherm. “We are excited to continue development of this unique technology to help clinicians control oxygenation, since both too much and too little oxygen have important clinical consequences. We see applications for this technology initially in the neonate patient population, and eventually for oxygen vulnerable adult patients as well.”
The IntellO2 works with the Precision Flow system, using pulse oximetry to monitor blood oxygen saturation and adjust inspired oxygen concentration settings accordingly. It utilizes a unique proprietary software algorithm designed to work with Hi-VNI® Technology. This study was conducted on a prototype device, and the system is currently not commercially available.
Vapotherm, Inc. (NYSE: VAPO) is a global medical technology company based in Exeter, New Hampshire that is focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1.5 million patients have been treated with Vapotherm Hi-VNI Technology. For more information, visit www.vapotherm.com.